Ferring
Ferring Pharmaceuticals, a global biopharmaceutical company headquartered in India, has established itself as a leader in reproductive health, urology, and gastroenterology since its founding in 1950. With a strong presence in Europe, North America, and Asia, Ferring is dedicated to developing innovative therapies that address unmet medical needs. The company is renowned for its core products, including hormone therapies and treatments for various gastrointestinal disorders, which are distinguished by their patient-centric approach and commitment to research and development. Ferring's notable achievements include pioneering advancements in assisted reproductive technology, solidifying its market position as a trusted provider of specialised healthcare solutions. Through its dedication to science and patient care, Ferring continues to make significant contributions to the biopharmaceutical industry.
DitchCarbon Score
How does Ferring's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ferring's score of 27 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ferring's reported carbon emissions
In 2023, Ferring reported total carbon emissions of approximately 580,198,000 kg CO2e, comprising 28,215,000 kg CO2e from Scope 1, 25,902,000 kg CO2e from Scope 2, and a significant 526,081,000 kg CO2e from Scope 3 emissions. This marks a notable increase in emissions compared to previous years, particularly from Scope 3, which includes emissions from purchased goods and services, business travel, and employee commuting. Ferring has committed to achieving net-zero emissions across all scopes by 2050, with a start year of 2023 for their long-term reduction targets. This commitment aligns with the Science Based Targets initiative (SBTi), indicating a structured approach to reducing their carbon footprint in the pharmaceutical sector. The company has demonstrated a proactive stance in addressing climate change, although specific reduction targets or achievements have not been disclosed. Ferring's ongoing efforts reflect a growing recognition of the importance of sustainability within the pharmaceutical industry, particularly in light of increasing regulatory and societal pressures to mitigate climate impacts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - | - | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | - | - | - | - | - | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ferring is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
